A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. A study on monkeys found that the vaccine provided them protection.
In May, the United States awarded the project $1.2 billion in support. Their Phase 1/2 trial revealed that the vaccine was safe, causing no severe side effects. It raised antibodies against the coronavirus as well as other immune defenses.
The vaccine is now in Phase 2/3 trials in England and India, as well as Phase 3 trials in Brazil, South Africa, and the United States.
In August the European Union reached an agreement for AstraZeneca to deliver 400 million doses if the trials yield positive results. AstraZeneca has indicated they might be able to start delivering emergency vaccines as early as October, depending on the outcome of the studies.
The company has said their total manufacturing capacity for the vaccine, if approved, stands at two billion doses. India’s Serum Institute has already produced millions of doses to be used in trials.
The Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences
. In May, they published promising results from a Phase 1 safety trial, and in July they reported that their Phase 2 trials demonstrated the vaccine produced a strong immune response.
In an unprecedented move, the Chinese military approved the vaccine on June 25 for a year as a “specially needed drug.” CanSino would not say whether vaccination would be mandatory or optional for soldiers.
On August 9, the Saudi health ministry announced that CanSino Biologics would run a Phase 3 trial in Saudi Arabia, and later in the month they also started a trial in Pakistan.
Moderna develops vaccines based on messenger RNA (mRNA) to produce viral proteins in the body. They have yet to bring one to the market. The government has bankrolled Moderna’s efforts on a coronavirus vaccine with nearly $1 billion. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus.
In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results, After carrying out a Phase 2 study they launched a Phase 3 trial on July 27.
The final trial will enroll 30,000 healthy people at about 89 sites around the United States. On August 11, the government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective.
In July, Moderna lost a patent dispute over some of their vaccine technology. The following month, the company stated that it could not be certain it was the first to make the inventions claimed in their patents, including its coronavirus vaccine.
0188 HLT, HLT GLOBAL BERHAD - + Additional Listing Announcement /Subdivision of Shares 4 Sep 2020, 07:00 Additional Listing Announcement /Subdivision of Shares 1. Details of corporate proposal Whether the corporate proposal involves the issuance of new type and new class of securities? N Types of corporate proposal : Exercise of Warrants Details of corporate proposal : Conversion of Warrants to Ordinary Shares No. of shares issued under this corporate proposal : 4,460,300 Issue price per share ($$) : 0.2000 Par Value ($$) (if applicable) : 0.000 Latest issued share capital after the above corporate proposal In the following Units : 582,381,749 Issued Share Capital ($$) : Malaysian Ringgit (MYR) 88,725,219.000 Listing Date : 07/09/2020 Remarks: You are advised to read the entire contents of the announcement or attachment. To read the entire contents of the announcement or attachment, please access the Bursa website at http://www.bursamalaysia.com
You only never ending excited 7 days a week. Attention freak, really like a street rat. Even careplus.page cursing u, such bad curse u keep.receiving, yet still ignorant.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Mikecyc
46,663 posts
Posted by Mikecyc > 2020-09-06 19:25 |
Post removed.Why?